Allogene Therapeutics, Inc. - Common Stock (ALLO)
Frequently Asked Questions About Allogene Therapeutics, Inc. - Common Stock (ALLO)
How does Allogene address safety concerns in its therapies?
Allogene Therapeutics prioritizes patient safety through rigorous preclinical studies and well-designed clinical trials. The company closely monitors safety and adverse events during trials, ensuring that any risks are adequately understood and managed before therapies are widely administered.
How does Allogene contribute to the scientific community?
Allogene Therapeutics actively contributes to the scientific community by publishing research findings, presenting at conferences, and collaborating with academic institutions. They aim to share knowledge and insights that can drive innovation and advance the field of cancer immunotherapy.
How does Allogene differentiate itself from competitors?
Allogene Therapeutics differentiates itself through its focus on allogeneic cell therapies, utilizing unique technological platforms, and targeting an array of diseases. Its ability to create off-the-shelf products offers a significant advantage in speed and accessibility compared to many competitors who utilize autologous therapies.
How is Allogene funded?
Allogene Therapeutics raises capital through a combination of public offerings, private investments, and partnerships. As a publicly traded company on the Nasdaq, it attracts investment from both institutional and retail investors interested in its innovative technology and growth potential.
What are the company's pipeline developments?
Allogene Therapeutics has a robust pipeline featuring various allogeneic CAR T cell therapies in various stages of development, targeting multiple cancer indications. The company continually works on advancing these candidates through clinical trials to determine their efficacy and safety for prospective patients.
What are the risks associated with investing in Allogene?
Investing in Allogene Therapeutics, like any biotech company, carries inherent risks including regulatory hurdles, clinical trial failures, and competitive pressures. Investors should be aware of the unpredictability in drug development and the need for significant capital to advance therapies through various stages.
What clinical trials is Allogene currently conducting?
Allogene Therapeutics is involved in several clinical trials to evaluate its lead products, which are designed to treat multiple types of cancers. These trials focus on assessing the safety, tolerability, and efficacy of their allogeneic CAR T therapies in patients.
What does Allogene Therapeutics, Inc. do?
Allogene Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of allogeneic T cell therapies for the treatment of cancer. The company focuses on harnessing the power of the immune system to fight cancers by creating genetically engineered T cells that can be produced off-the-shelf for patients.
What is ALLO-501 and ALLO-501A?
ALLO-501 is an investigational allogeneic CAR T cell therapy targeting CD19, designed for treating B-cell malignancies such as non-Hodgkin lymphoma. ALLO-501A is an enhanced version of ALLO-501 with potential improvements aimed at increasing efficacy and safety in treating patients.
What is allogeneic T cell therapy?
Allogeneic T cell therapy refers to the use of T cells derived from a healthy donor rather than the patient themselves. This approach allows for the creation of standardized, off-the-shelf therapies that can be readily available to patients, potentially speeding up treatment times and reducing costs.
What is the company's vision for the future?
Allogene Therapeutics envisions a future where allogeneic cell therapies become mainstream treatment options for cancer patients. The company aims to advance its scientific research, expedite clinical development, and ultimately provide cost-effective and accessible therapies that improve patient outcomes.
What is the corporate culture at Allogene?
The corporate culture at Allogene Therapeutics emphasizes innovation, collaboration, and a commitment to patient care. This culture fosters an environment where employees are encouraged to share ideas and work collectively towards the common goal of developing life-saving therapies for cancer.
What is the significance of off-the-shelf therapies?
Off-the-shelf therapies, like those developed by Allogene, provide patients with immediate access to treatment without the lengthy manufacturing processes associated with personalized therapies. This approach can enhance patient care by reducing time to treatment and facilitating broader patient recruitment in clinical settings.
What partnerships does Allogene Therapeutics have?
Allogene Therapeutics has formed strategic partnerships with leading biotech and pharmaceutical companies, research institutions, and academic centers. These collaborations enhance Allogene's research capabilities, facilitate access to resources, and accelerate the development and commercialization of its therapies.
What role does the FDA play in Allogene's product development?
The U.S. Food and Drug Administration (FDA) plays a critical role in Allogene's product development by overseeing the regulatory approval process for its therapies. Allogene must submit investigational new drug applications (INDs) and secure FDA approval for clinical trials and eventual commercialization of its therapies.
What technologies does Allogene Therapeutics use in its therapies?
Allogene Therapeutics employs proprietary technologies, including its AlloCAR T cell platform, which enables the development of allogeneic CAR (Chimeric Antigen Receptor) T cells. This technology aims to provide effective and safer treatment options compared to traditional autologous approaches.
What types of cancer does Allogene Therapeutics target?
Allogene Therapeutics primarily focuses on various types of hematological malignancies and solid tumors, including but not limited to leukemia and lymphoma. The goal is to develop effective treatments for a wide range of cancer types using innovative T cell therapies.
When was Allogene Therapeutics founded?
Allogene Therapeutics was founded in 2018 by a group of experienced biotech professionals, including pioneers in the field of CAR T cell therapy. The company was established to leverage advances in cell therapy and create innovative treatments for cancer patients.
Where is Allogene Therapeutics headquartered?
Allogene Therapeutics is headquartered in South San Francisco, California, a region known for its vibrant biotechnology community. This strategic location allows the company to engage and collaborate with other industry leaders and research institutions.
What is the current price of Allogene Therapeutics, Inc. - Common Stock?
The current price of Allogene Therapeutics, Inc. - Common Stock is 1.430
When was Allogene Therapeutics, Inc. - Common Stock last traded?
The last trade of Allogene Therapeutics, Inc. - Common Stock was at 2:55 pm EDT on April 4th, 2025
What is the market capitalization of Allogene Therapeutics, Inc. - Common Stock?
The market capitalization of Allogene Therapeutics, Inc. - Common Stock is 203.32M
How many shares of Allogene Therapeutics, Inc. - Common Stock are outstanding?
Allogene Therapeutics, Inc. - Common Stock has 142.18M shares outstanding.